Addex Therapeutics (ADXN) updates interim 2025 financials in Form 6-K

Rhea-AI Filing Summary

Addex Therapeutics Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish its unaudited interim condensed consolidated financial statements and related commentary for the periods ended June 30, 2025. The filing includes financial statements, management’s discussion and analysis of financial condition and results of operations, and a press release dated September 30, 2025.

The company states that Exhibits 99.1 and 99.2 are incorporated by reference into its existing shelf registration on Form F-3 and its Form S-8 registration statements, meaning these updated interim figures and discussions now form part of those registration documents. The report reiterates that Addex faces significant risks described in its prior Form 20-F and that forward-looking statements are subject to those risks.

Form 6-K: How Foreign Companies Report to the SEC →

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

September 2025

​

​

Commission File Number: 001-39179

​

​

Addex Therapeutics Ltd

(Exact Name of Registrant as Specified in Its Charter)

​

​

Chemin des Mines 9,

CH-1202 Geneva,

Switzerland

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F ☒ Form 40-F ☐

​

​

​

​

INCORPORATION BY REFERENCE

​

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

​

RISK FACTORS

​

Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on May 15, 2025. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings.

​

​

2

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​	​	​	​	​
​	​	Addex Therapeutics Ltd
​	​	​	​
​	​	By:	/s/ Tim Dyer
​	​	​	Name:	Tim Dyer
Date: September 30, 2025	​	​	Title:	Chief Executive Officer

​

​

​

​

3

​

EXHIBIT INDEX

​

​	​	​
Exhibit No.		Description
Exhibit 99.1 :	​	Unaudited Interim Condensed Consolidated Financial Statements
Exhibit 99.2 :	​	Management’s Discussion and Analysis of Financial Condition and Result of Operations
Exhibit 99.3 :	​	Press Release dated September 30, 2025
101.INS	​	The following materials from this Report on Form 6-K are formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024; (ii) Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and the six-month periods ended June 30, 2025 and 2024; (iii) Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the six-month periods ended June 30, 2025 and 2024; (iv) Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the three-month periods ended June 30, 2025 and 2024; (v) Unaudited Interim Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2025 and 2024; and (vi) Unaudited Notes to the Interim Condensed Consolidated Financial Statements for the three-month and six-month periods ended June 30, 2025.

​

4

FAQ

What did Addex Therapeutics Ltd (ADXN) file in this Form 6-K?

Addex Therapeutics Ltd filed a Form 6-K as a foreign private issuer to provide unaudited interim condensed consolidated financial statements, related management’s discussion and analysis, and a press release dated September 30, 2025.

Which periods do Addex Therapeutics Ltd’s interim financial statements in this 6-K cover?

The interim financial information includes unaudited interim condensed consolidated balance sheets as of June 30, 2025 and December 31, 2024, and statements of comprehensive loss, changes in equity, and cash flows for the three-month and six-month periods ended June 30, 2025 and 2024.

How does this Addex Therapeutics Ltd (ADXN) 6-K interact with its existing registration statements?

The company states that Exhibits 99.1 and 99.2 from this Form 6-K are incorporated by reference into its Form F-3 registration statement (No. 333-255089) and its Form S-8 registration statements (Nos. 333-255124 and 333-272515), making these materials part of those registrations.

What risk information does Addex Therapeutics Ltd highlight in this 6-K?

Addex emphasizes that its business faces significant risks and directs readers to the risk factors in its Annual Report on Form 20-F for the year ended December 31, 2024, filed on May 15, 2025, and to other SEC filings. It notes that forward-looking statements in the materials are subject to these risks.

Who signed the Addex Therapeutics Ltd Form 6-K and when?

The Form 6-K was signed on behalf of Addex Therapeutics Ltd by Tim Dyer, its Chief Executive Officer, dated September 30, 2025.

What additional technical exhibit format is included in this Addex Therapeutics Ltd 6-K?

The filing includes an exhibit identified as 101.INS, which contains the interim financial statements and notes formatted in Inline XBRL (iXBRL) for the three-month and six-month periods ended June 30, 2025 and 2024.